

ASSISTED TRAINING THROUGH VIDEOS

Delivering highly engaging training using video, audio, and animation that results in increased understanding and retention.

Assisted Training Through Videos

The screenshot shows a web browser interface for a patient education site. At the top, there are links for 'Become a VOC Club Member', 'Contact Novartis', and 'Important Safety Information'. Below this is a navigation bar with 'HOME', 'BACK', 'FORWARD', and 'For Your Patients | What's New for Patients?'. A left sidebar contains a menu with items like 'Oncology Clinic', 'Infusion Suite', 'Radiology', 'Laboratory and Pharmacy', 'Reimbursement Center', 'For Your Patients', 'What's New for Patients?', 'Print Materials', 'Patient Web Site Links', and 'Site Map'. The main content area features a video of a woman in blue scrubs standing in a clinical setting. To the right of the video is a sidebar with a 'Click here for Marcia's Facebook page' link, a 'Print Materials' link with a PDF icon, and a 'Patient Web Site Links' link with a globe icon. A 'Skip Video' button is located at the bottom center of the video frame.

INDICATION | zoledronic acid (zoledronic acid) is indicated for the treatment of hypercalcemia of malignancy (HCM) and patients with multiple myeloma and documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Safe and efficacious use of zoledronic acid has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.

IMPORTANT SAFETY INFORMATION | zoledronic acid is contraindicated in patients with hypersensitivity to zoledronic acid or any components of zoledronic acid. Hypersensitivity reactions, including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock, have been reported. Patients being treated with zoledronic acid should not be treated with Reclast as they contain the same active ingredient.


Patients with HCM must be adequately rehydrated prior to use of zoledronic acid and, less duration (if applicable). Less duration should be used with caution in combination

Assisted Training Through Videos

Become a VOC Club Member Contact Novartis Important Safety Information 


HOME BACK FORWARD Oncology Clinic | What's New in the Clinic?

- Oncology Clinic ▾
- ▶ What's New in the Clinic?
- ▶ Patient Cases
- ▶ Q&A Videos
- ▶ Web Conferences and Congresses
- ▶ Resources for Physicians
- Infusion Suite ▾
- Radiology ▾
- Laboratory and Pharmacy ▾
- Reimbursement Center ▾
- For Your Patients ▾
- Site Map



Watch case-based web conferences presented by leading oncologists.


Click here for links to web conferences.



Fred Saad MD


Patient Cases

Interactive patient cases developed by leading oncologists/hematologists.




Q&A Videos

A collection of question and answer videos including interviews with leading oncologists and hematologists.




Web Conferences and Congresses

Web conferences featuring leading oncologists and information on key oncology congresses.



Resources for Physicians

Multimedia resources including reprints and materials, links to oncology associations, and practice guidelines.



To Evaluate Renal Function

CREATININE CLEARANCE CALCULATOR

[CLICK HERE](#)

INDICATION | zoledronic acid (zoledronic acid) is indicated for the treatment of hypercalcemia of malignancy (HCM) and patients with multiple myeloma and documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Safe and efficacious use of zoledronic acid has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.

IMPORTANT SAFETY INFORMATION | zoledronic acid is contraindicated in patients with hypersensitivity to zoledronic acid or any components of zoledronic acid. Hypersensitivity reactions, including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock, have been reported. Patients being treated with zoledronic acid should not be treated with Reclast as they contain the same active ingredient.

Patients with HCM must be adequately rehydrated prior to use of zoledronic acid and loop diuretics (if applicable). Loop diuretics should be used with caution in combination with zoledronic acid to avoid hypocalcemia. zoledronic acid should be used with caution with other nephrotoxic drugs. Carefully monitor serum calcium, phosphate, magnesium

Assisted Training Through Videos

Virtual Training Center


Choose a floor from the left to begin your training, or quick-jump to a floor/topic below:

Each floor represents a separate topic.

FLOOR/TOPIC TITLE	DURATION	% COMPLETE	PRINT
FLOOR ONE: Topic 1: Title			LAUNCH >
FLOOR TWO: Topic 2: Title			LAUNCH >
FLOOR THREE: Topic 3: Title			LAUNCH >
FLOOR FOUR: Topic 4: Title			LAUNCH >
FLOOR FIVE: Topic 5: Title			LAUNCH >
FLOOR SIX: Topic 6: Title			LAUNCH >
FLOOR SEVEN: Topic 7: Title			LAUNCH >
FLOOR EIGHT: Topic 8: Title			LAUNCH >
FLOOR NINE: Topic 9: Title			LAUNCH >
FLOOR TEN: Topic 10: Title			LAUNCH >
FLOOR ELEVEN: Topic 11: Title			LAUNCH >

Assisted Training Through Videos

Introduction | Course Structure



- ### Course Structure
- **Module 1: People** – The talent within an agency, their roles and responsibilities
 - **Module 2: Process** – The method of asset development from creation to execution
 - **Module 3: Partnering** – What it takes to create a successful partnership

SHOW TRANSCRIPT TEXT

Navigation icons: question mark, open book, home, search, play/pause, volume, page 3 of 9, left/right arrows.

Assisted Training Through Videos

Active Listening | Interpret the Meaning

SHOW TRANSCRIPT TEXT

4 / 8



To learn more about how we can help your organization, please contact:



Marketing.global@indegene.com



www.indegene.com/lifesciences



trainingsolutions.indegene.com